Atrium Therapeutics Inc (RNA)

Atrium Therapeutics Inc stock is traded at $8.44, with a volume of 101,745. It is down -2.82% in the last 24 hours and up +5.83% over the past month. Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.